




# Dental treatment needs in hospitalized cancer patients: a retrospective cohort study

Maria Cecilia Querido de Oliveira<sup>1,2</sup> · Beatriz Nascimento F. Lebre Martins<sup>1</sup> · Alan Roger Santos-Silva<sup>1</sup> · César Rivera<sup>3</sup> · Pablo Agustin Vargas<sup>1</sup> · Márcio Ajudarte Lopes<sup>1</sup> · Aljomar Jose Vechiato-Filho<sup>2</sup> · Thaís Bianca Brandão<sup>4</sup> · Ana Carolina Prado-Ribeiro<sup>1,2</sup> 

Received: 18 July 2019 / Accepted: 22 November 2019 / Published online: 4 December 2019

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

## Abstract

**Purpose** The objectives of this study were to describe the distribution and the clinicopathological features of the most common causes for dental treatment needs during the hospitalization of cancer patients.

**Methods** A retrospective cohort study of 2664 hospitalized cancer patients that analyzed the main dental treatment needs and dental procedures performed from January 2010 to December 2017.

**Results** A total of 2664 medical patients were included in this study. Non-Hodgkin lymphoma (17.2%) was the most common cancer type, followed by leukemia (14.8%), and oral and oropharyngeal squamous cell carcinoma (10.5%). The most common reasons for patients' hospitalization were chemotherapy protocols (18.8%), monitoring head and neck surgeries (9.7%), and febrile neutropenia (9.6%). The main motivation for the medical team to request dental evaluation was oral mucositis (22.8%) followed by oral pain or toothache (10.8%) and fungal, viral oral infections or traumatic oral lesions (9.9%). The dental treatment needs most observed were pain due to oral mucositis (17%), dental treatment prior to radiotherapy (RT), chemotherapy (CT) or bisphosphonate therapy (BP) (10.8%), teeth extractions (6.5%), and prophylactic photobiomodulation therapy (6.3%), whereas the most common dental treatments performed were oral hygiene protocols (30.2%), photobiomodulation therapy (prophylactic and curative) (21.7%), and dental treatment prior to cancer treatment initiation (RT, CT, and BP) (9.5%).

**Conclusion** This study can be considered original in the oncologic context, providing new information about the most frequent dental treatment needs among a large population of hospitalized cancer patients.

**Keywords** Mouth neoplasms · Oral squamous cell carcinoma · Oral mucositis · Oral dental care

## Introduction

In 2018, the GLOBOCAN database presented an estimate of 18.1 million new cancer cases diagnosed worldwide and 9.6 million

cancer-related deaths. In this scenario, malignant tumors of the lung, breast, prostate, skin, and oral cavity, as well as hematologic and lymphatic tumors are the most frequent cancer types [1, 2].

Cancer patients are often treated by surgery (SG), chemotherapy (CT), radiotherapy (RT), bone marrow transplantation, molecular targeted therapy, or a combination of these methods. The main causes of hospitalizations among cancer patients are symptoms related to disease progression or by toxicities (side effects) of oncologic treatment. In this context, impaired dental hygiene and oral lesions may lead to high rates of local (odontogenic infections) and systemic infections, such as respiratory diseases (ventilator-associated pneumonia), which have the potential to cause delays in, or interruptions to cancer treatment, as well as a decrease in the quality of life of patients. These oral complications secondary to cancer progression or related to oncologic treatment may also increase the overall treatment cost, due to the need for special

✉ Ana Carolina Prado-Ribeiro  
carol\_pr@yahoo.com.br

<sup>1</sup> Oral Diagnosis Department, Piracicaba Dental School, UNICAMP, Piracicaba, Brazil

<sup>2</sup> Serviço de Odontologia Oncológica, Instituto do Câncer do Estado de São Paulo, ICESP-FMUSP, Faculdade de Medicina da Universidade de São Paulo, Av. Doutor Arnaldo, 251 Cerqueira César, São Paulo CEP 01246-000, Brazil

<sup>3</sup> Department of Basic Biomedical Sciences, Universidad de Talca, Talca, Chile

<sup>4</sup> Odontologia Oncológica D'or, São Paulo, Brazil

diet (feeding tubes), analgesia with opioids, and prolonged hospitalization [3–9]. However, most of the previously published studies in this field focused on describing systemic complications in hospitalized cancer patients [8, 10, 11].

Although oral mucositis (OM), odontogenic (dental caries, abscesses, and periodontal disease), viral (herpes simplex virus) and fungal (oral candidosis) infections, and other soft tissue and jawbone lesions have been previously demonstrated as common oral complications among cancer patients in intensive care units [5, 8, 10–13], the patterns of oral complications and dental treatment needs among cancer inpatients are widely unknown.

Therefore, the aim of this study was to describe the distribution and the clinicopathological features of the most common causes of dental treatment needs among patients during the hospitalization period in infirmaries of a major cancer facility in Latin America.

## Patients and methods

The present study was approved by the Ethics Committee of the School of Medicine of the University of Sao Paulo (Protocol no. 2.580.090), Sao Paulo, Brazil. This was a retrospective cohort study that analyzed the main dental treatment needs and dental procedures performed in hospitalized cancer patients treated at São Paulo State Cancer Institute (ICESP), Brazil, from January 2010 to December 2017. This study was performed following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [14].

## Data collection

All patients included in this study were evaluated by the members of the Dental Oncology Service of ICESP during the hospitalization period following digital medical requests performed through the institutional electronic medical record system (Tasy, Java version; product #NOCTN306, Koninklijke Philips N.V., 2004–2017).

Patients' epidemiologic and demographic data were retrieved and collected from the institutional electronic medical record system Tasy (Philips Clinical Informatics, Blumenau, Brazil), including gender, age, cancer diagnosis, clinical staging (according to the TNM Classification of Malignant Tumors (TNM); American Joint Committee on Cancer Staging System, 7th edition) [15], cancer treatment protocols, reasons for hospitalization, and medical specialties that requested a dental evaluation.

Clinicopathological aspects of the oral or dental complications that originated the medical requested as well as the

patterns of dental treatment needs were also collected and further studied.

Anatomical sites of primary tumors of included patients were reported according to the International Classification of Diseases for Oncology (ICD–O–3, International Agency for Research on Cancer; see in <https://www.iarc.fr>).

## Inclusion criteria

All hospitalized cancer patients presenting complete medical records who demanded dental assessment following medical requests in the study's period were included.

## Exclusion criteria

Subjects who refused oral evaluations or received medical discharge prior to oral examination were excluded from the study.

## Statistical analysis

Data were analyzed with descriptive statistics (frequency and percent) using Microsoft Excel 2013 (Microsoft Corporation, Seattle, USA) and SPSS statistical package 17 for Windows (IBM, Chicago, USA) [16].

## Results

### Clinical features

During the period of this retrospective cohort study, 137,279 patients were hospitalized at ICESP; of these, 3010 (2.20%) were evaluated by the Dental Oncology Service, following medical request. Three hundred and forty-six (11.5%) of these patients presented incomplete medical records or were patients who received medical discharge prior to oral examination, so they were excluded from the analyses. Hence, 2664 (1.95%) patients were included in this study.

### Hospitalization

The mean time of hospitalization for studied patients was 3.2 days. Analysis by gender showed that 1513 (56.8%) patients were male, whereas 1151 (43.2%) were female. The patients' ages ranged from 16 to 90 years and the mean age at hospitalization was 53.1 years. The most common cancer type was non-Hodgkin lymphoma (459 (17.2%)), followed by leukemia (395 (14.8%)), oral cavity, and oropharyngeal squamous cell carcinomas (280 (10.5%)) and multiple myeloma (174

(6.5%). The patients were most frequently (1178; (44.2%)) diagnosed under a clinically advanced stage of diseases (III/IV). Patients undergoing or following CT protocols were those who more frequently demanded dental evaluation during the course of hospitalization (Table 1).

The most common medical reasons for patients' hospitalization were CT protocols (especially hematological patients) (502; (18.8%)), hospitalizations for monitoring head and neck surgeries (258; (9.7%)), and febrile neutropenia (FN) (226; (8.5%)). Of the 226 patients with FN, 78 (34.5%) presented OM during the evaluation and 57 (25.2%) required dental procedures (tooth extraction due to abscesses or periodontal disease). Toothache was a "top five" cause for hospitalization (165; (6.2%)) among cancer patients.

### Dental second opinion and treatment

The main motivation for the medical team to request dental evaluation were OM (607; (22.8%)) followed by oral pain or toothache (287; (10.8%)), fungal, viral oral infections, or traumatic oral lesions (263; (9.9%)) and prophylactic photobiomodulation therapy (241; (9%)). The medical specialties that requested dental assessment more frequently were clinical oncology (1080; (40.5%)), hematology (879; (33%)), intensive care (320; (12%)), and head and neck surgery (137; (5.2%)) (Table 2).

The most prevalent dental treatment needs observed in hospitalized cancer patients were pain due to OM (453; (17%)), dental treatment prior to the RT, CT, or bisphosphonates therapy (BP) (286; (10.8%)), teeth extractions (173; (6.5%)), and prophylactic photobiomodulation therapy (170; (6.3%)), whereas the most common dental treatments performed were oral hygiene protocols (806; (30.2%)), photobiomodulation therapy (prophylactic and curative) (577; (21.7%)), dental treatment prior to cancer treatment initiation (RT, CT, and BP) (254; (9.5%)), and teeth extraction (204; (7.7%)) (Table 3).

### Discussion

This seems to be the first study in the English-language literature to analyze the patterns of dental needs in hospitalized oncologic patients from a Latin American population. This particular study was performed in the biggest public cancer hospital in Brazil, which provides medical assistance for patients of the entire country and, thus, may be considered a representative sample in oncologic terms as well as regarding the occurrence of oral complications in cancer inpatients. However, it is important to mention that the clinical demand reported in this study (1.95% of the hospital population) was based on patients who had a medical request for dental assistance/treatment. A prospective study with a proper sample size

**Table 1** Clinicopathological features of patients included in this study

Demographic features	N. patients (%)
Gender	
Male	1513 (56.8)
Female	1151 (43.2)
Age	
10–19	21 (0.8)
20–29	287 (10.8)
30–39	294 (11.0)
40–49	388 (14.6)
50–59	652 (24.5)
60–69	611 (22.9)
70–79	314 (11.8)
80–89	92 (3.4)
90+	5 (0.2)
Cancer diagnosis*	
Non-Hodgkin lymphoma	459 (17.2)
Leukemia	395 (14.8)
Oral and oropharyngeal carcinoma	280 (10.5)
Multiple myeloma	174 (6.5)
Breast cancer	159 (6.0)
Lung cancer	99 (3.7)
Rectum cancer	75 (2.8)
Colon cancer	60 (2.3)
Laryngeal carcinoma	60 (2.3)
Nasopharyngeal carcinoma	52 (2.0)
Others	851 (31.9)
Cancer staging**	
In situ	2 (0.08)
I	50 (1.9)
II	97 (3.6)
III	155 (5.8)
IV	1023 (38.4)
Unknown	1337 (50.22)
Cancer treatment stage during hospitalization	
Treatment planning	129 (4.8)
After SG	318 (12.0)
Before CT	268 (10.0)
Ongoing CT	385 (14.5)
After CT	807 (30.3)
Before RT	62 (2.3)
Ongoing RT	133 (5.0)
Palliative care	69 (2.6)
Others	493 (18.5)

N, total number

\*Anatomic sites classified according to the International Classification of Diseases for Oncology.

\*\*According to the TNM Classification of Malignant Tumors (TNM); American Joint Committee on Cancer Staging System, 7th edition.

SG, surgery

CT, chemotherapy

RT, radiotherapy

calculation will be necessary to confirm the results of this large cohort retrospective study.

The most recent report of GLOBOCAN [1] showed that the highest incidence of tumors in men was lung (14.5%) and prostate (13.5%) cancer, while in women it was breast

**Table 2** Hospitalization features of 2664 hospitalized oncological patients

Features	No. patients (%)
Reason for hospitalization	
Chemotherapy protocols	502 (18.8)
Head and neck surgery recovery	258 (9.7)
Septic shock	238 (8.9)
Febrile neutropenia	226 (8.5)
Toothache	165 (6.2)
Secondary tumor infection	101 (3.8)
Fever	84 (3.2)
Conclusion of cancer diagnoses	64 (2.4)
Oral mucositis	60 (2.3)
Bleeding	59 (2.2)
Others	877 (32.9)
Medical request motivation	
Oral mucositis	607 (22.8)
Oral pain/toothache	287 (10.8)
Fungal, viral infections, or traumatic lesions	263 (9.9)
Prophylactic photobiomodulation therapy	241 (9.0)
Poor dental health	173 (6.5)
Oral examinations*	150 (5.6)
Odontogenic infections**	90 (3.4)
Pre-bisphosphonates administration	88 (3.3)
Prescription of chlorhexidine mouthwash	75 (2.8)
Assisted oral hygiene	72 (2.7)
Others	618 (23.2)
Medical specialties who requested dental assessment	
Clinical oncology	1080 (40.5)
Hematology	879 (33.0)
Intensive Care	320 (12.0)
Head and Neck Surgery	137 (5.2)
Palliative Care	50 (1.9)
Digestive Surgery	24 (0.9)
Urology	23 (0.8)
Plastic Surgery	22 (0.8)
Sarcoma and melanoma surgery	21 (0.7)
Anesthesiology	12 (0.5)
Others	96 (3.7)
Dental treatment needs	
Pain due to oral mucositis	453 (17.0)
Dental treatment prior to cancer treatment initiation (RT/CT/BP)	286 (10.8)
Teeth extraction	173 (6.5)
Prophylactic photobiomodulation therapy	170 (6.3)
Absence of dental complication	150 (5.6)
Oral candidiasis	148 (5.5)
Oral herpes	137 (5.1)
Traumatic ulcers	100 (3.8)
Oral hygiene protocols	87 (3.3)
Dental abscesses	58 (2.2)
Others	902 (33.9)

\*Physician required a non-specific evaluation, patient was not able to describe the dental complaint to the medical team, or the physician was not able to diagnose it.

\*\*Physician ruled out focus of infection in others sites, except oral cavity as a possible source of fever

RT, radiotherapy

CT, chemotherapy

BP, biphosphonate

**Table 3** Dental treatment of the hospitalized cancer patients

Dental treatment	N. patients (%)
Oral hygiene protocols	806 (30.2)
Photobiomodulation therapy (prophylactic and curative)	577 (21.7)
Dental treatment prior to cancer treatment initiation (RT/CT/BP)	254 (9.5)
Teeth extraction	204 (7.7)
Antifungal treatment	143 (5.4)
Antiviral treatment	120 (4.5)
Oral lubricant treatment	52 (2.0)
Obturator prosthesis	42 (1.6)
Oral analgesics to oral pain relief	39 (1.5)
Others	427 (15.9)

(24.2%) and lung (8.4%) cancer. In the present study, the majority of hospitalized cancer patients evaluated were undergoing treatment for hematologic neoplasms (32%) and oral cavity and oropharyngeal cancer (15.3%), and this difference may result from the fact that oral toxicities are frequently more related to the cancer therapy performed than to the types of cancer. However, breast and lung cancers were also among the “top ten” malignant tumors of the population studied herein.

It is important to highlight that São Paulo State Cancer Institute is a quaternary cancer care center designed to assist highly complex cases in oncology. Thus, most of the patients (44.2%) included in this retrospective cohort study were undergoing treatment for advanced malignant tumors. Hence, the high demand for dental second opinions can be justified by the intense treatment protocols used in this inpatient service, such as aggressive surgeries combined with radiotherapy and chemotherapy.

Oncologic patients often require hospitalization not only for treating their malignant neoplasms (SG, CT, or RT) [2, 7, 8] but also due to toxicities resulting from cancer treatment [5, 12, 13, 17], or even for unpredictable needs that should preferably be managed in hospital facilities, such as opportunistic infections [11]. Approximately, 40% of CT-treated patients develop OM [10, 17]. The present study showed that the main reason for hospitalization was associated with complications of CT protocols (18.8%), in accordance with the findings reported by Gomes et al. (2018) [10], who described higher rates of hospitalization due to CT or toxicities related to the treatment.

Also, Numico et al. [11] performed a retrospective study with cancer patients and described that cancer treatment-related toxicities were the main reason (80.2%) for hospital admission. In our study, the main complications related to the oncological treatment were similar to those in Numico et al.’s [11] report, such as FN (9.6%), septic shock (8.9%), and OM (2.3%). In our sample, from 226 patients with FN, 78 (34.5%) had OM and 57 (25.2%) required dental procedures related to surgical and periodontal treatments (tooth extraction, draining

of dental abscesses, or periodontal therapy, for example). The present study supports previous observations about the association of OM, periodontal diseases, and FN in hospitalized cancer patients [18–20].

As previously described in oncologic patients, OM is a common complication, which may result in severe pain, nutritional impairment, and increase the risk of local and systemic infections [21, 22]. Our results showed that OM was the most common oral alteration diagnosed in the evaluated population (17%), which was corroborated by the fact that it was also a leading (22.8%) reason for a dental evaluation request by the medical team. Remarkably, in this scenario, 577 (21.7%) patients demanded photobiomodulation therapy (prophylactic and curative) following institutional protocols previously published by our group [21].

The high rates of OM diagnosed among the patients included in this study were the consequence of the fact that most patients were undergoing systemic treatments for advanced cancer that were mostly based on cytotoxic CT protocols. This scenario may justify the high demand of medical requests performed by clinical oncology (1080; 40.5%) and hematology (879; 33%) medical teams.

It is relevant to mention that when it comes to the “top ten” cancers diagnosed in the current population, the frequency of hematological malignant tumors (38.5%) was similar to solid malignant tumors (29.6%). However, there was a broader distribution of entities in the scope of clinical oncology (oral carcinoma, oropharyngeal carcinoma, breast cancer, lung cancer, rectum cancer, laryngeal carcinoma, and nasopharyngeal carcinomas) than in the hematology context (non-Hodgkin lymphoma, leukemia, and multiple myeloma). In addition, most of the cancer diagnoses out of the “top ten” category and listed as “others” represent solid tumors in the treatment context of clinical oncology. In fact, as observed in the cohort of the study patients, the most commonly admitted cancer patients during cancer treatment or at the initiation of the treatments are those with hematological malignancies or aggressive solid tumors because oral toxicities are often more



closely related to the cancer therapy performed than to the type of cancer.

Oral and oropharyngeal cancer (15.3%) were listed in the “top three” malignant tumors among the hospitalized population in this study, and this might explain why the Head and Neck Surgery team was the fourth specialty that requested dental evaluation more frequently. The treatment of oral and oropharyngeal cancer can involve SG, CT, and head and neck RT (HNRT) or a combination of these methods. However, although effective in tumor control, these treatments are associated with surgical sequelae, oral toxicities, and a consequent reduction in the quality of life of cancer populations [23, 24]. In this context, multidisciplinary teams are core to supporting these patients. The present study showed that the main dental treatment performed included oral hygiene protocols (30.2%), photobiomodulation therapy (prophylactic and curative) (21.7%), dental treatment prior to oncologic treatment (9.5%), and confection of obturator prosthesis (1.6%).

Fungal and virus infections in the oral cavity are common in immunocompromised patients [10, 25, 26]. Similarly, our results showed a prevalence of 5.6 and 5.1% for oral candidiasis and oral herpes simplex, respectively; while in previously published retrospective studies evaluating oncologic inpatients, the incidences ranged from 16.6 to 39.1% [3, 9–11]. This difference may be attributed to the evaluation of hospitalized patients with several cancer diagnoses as well as the variety of reasons that lead to their hospitalizations.

In conclusion, this study suggests that patients with hematological malignancies and head and neck cancer present higher dental treatment needs during the period of hospitalization, mainly because of oral pain due to OM, dental conditioning prior to cancer therapy, teeth extractions, and prophylactic photobiomodulation therapy, whereas the most common dental treatments performed were oral hygiene protocols, photobiomodulation therapy (prophylactic and curative), dental treatment prior to cancer treatment initiation, and teeth extraction.

Although this large cohort study originally reported the patterns of dental treatment needs in hospitalized cancer patients, generating results with the potential to clarify inpatients’ dental necessities and also to support managers in organizing dental teams in similar hospital settings, there are limitations to be considered, such as its retrospective nature, the lack of sample size calculation, and the fact that most diagnoses were mainly based on physician evaluation.

### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** The present study was approved by the Ethics Committee of the School of Medicine of the University of Sao Paulo (Protocol no. 2.580.090), Sao Paulo, Brazil.

**Control of the Data** The authors have full control of all primary data and agree to allow the journal to review our data if requested.

### References

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 144(8):1941–1953. <https://doi.org/10.1002/ijc.31937>
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136(5):E359–E386. <https://doi.org/10.1002/ijc.29210>
3. Silva AP, Caruso P, Jaguar GC, Carvalho PA, Alves FA (2014) Oral evaluation and procedures performed by dentists in patients admitted to the intensive care unit of a cancer center. *Support Care Cancer* 22(10):2645–2650. <https://doi.org/10.1007/s00520-014-2233-0>
4. Davies AN, Brailsford SR, Beighton D (2006) Oral candidosis in patients with advanced cancer. *Oral Oncol* 42(7):698–702. <https://doi.org/10.1016/j.oraloncology.2005.11.010>
5. Tai E, Guy GP, Dunbar A, Richardson LC (2017) Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. *J Oncol Pract* 13(6):e552–e561. <https://doi.org/10.1200/JOP.2016.019588>
6. Fischer DJ, Epstein JB, Yao Y, Wilkie DJ (2014) Oral health conditions affect functional and social activities of terminally ill cancer patients. *Support Care Cancer* 22(3):803–810
7. Lee MK, Dodson TB, Nalliah RP, Karimbux NY, Allareddy V (2014) Nine-year trend analysis of hospitalizations attributed to oral and oropharyngeal cancers in the United States. *Oral Surg Oral Med Oral Pathol Oral Radiol* 118(1):47–67. <https://doi.org/10.1016/j.oooo.2013.01.019>
8. Lee MK, Nalliah RP, Kim MK, Elangovan S, Allareddy V, Kumar-Gajendrareddy P, Allareddy V (2011) Prevalence and impact of complications on outcomes in patients hospitalized for oral and oropharyngeal cancer treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 112(5):581–591. <https://doi.org/10.1016/j.tripleo.2011.06.032>
9. Lev A, Aied AS, Arshed S (2015) The effect of different oral hygiene treatments on the occurrence of ventilator associated pneumonia (VAP) in ventilated patients. *J Infect Prev* 16(2):76–81. <https://doi.org/10.1177/1757177414560252>
10. Gomes AOF, Silva Junior A, Noce CW, Ferreira M, Maiolino A, Torres SR (2018) The frequency of oral conditions detected in hematology inpatients. *Hematol Transfus Cell Ther* 40(3):240–244. <https://doi.org/10.1016/j.htct.2018.02.006>
11. Numico G, Cristofano A, Mozzicafreddo A, Cursio OE, Franco P, Courthod G, Trogu A, Malossi A, Cucchi M, Sirotoà Z, Alvaro MR, Stella A, Grasso F, Spinazzè S, Silvestris N (2015) Hospital admission of cancer patients: avoidable practice or necessary care? *PLoS One* 10(3):e0120827. <https://doi.org/10.1371/journal.pone.0120827>
12. Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. *Oncologist* 17(1):135–144. <https://doi.org/10.1634/theoncologist.2011-0111>
13. Terezakis E, Needleman I, Kumar N, Moles D, Agudo E (2011) The impact of hospitalization on oral health: a systematic review. *J Clin*

- Periodontol 38(7):628–636. <https://doi.org/10.1111/j.1600-051X.2011.01727.x>
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative STROBE (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J Surg* 12(12):1495–1499. <https://doi.org/10.1016/j.ijsu.2014.07.013>
  15. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 17(6):1471–1474
  16. Stephen BH, Steven RC, Thomas BN (2011) Designing cross-sectional and cohort studies. In: Smith J (ed) *Designing clinical research*, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 85–96
  17. de Lacerda Vidal CF, Vidal AK, Monteiro JG Jr, Cavalcanti A, Henriques APC, Oliveira M, Godoy M, Coutinho M, Sobral PD, Vilela CÂ, Gomes B, Leandro MA, Montarroyos U, Ximenes RA, Lacerda HR (2017) Impact of oral hygiene involving toothbrushing versus chlorhexidine in the prevention of ventilator-associated pneumonia: a randomized study. *BMC Infect Dis* 17(1):112. <https://doi.org/10.1186/s12879-017-2188-0>
  18. Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F (2019) Mucosal injury during anti-cancer treatment: from pathobiology to bedside. *Cancers (Basel)* 11(6):857. <https://doi.org/10.3390/cancers11060857>
  19. Fernandes LL, Torres SR, Garnica M, de Souza GL, Junior AS, de Vasconcellos AC, Cavalcanti W, Maiolino A, de Barros Torres MC (2014) Oral status of patients submitted to autologous hematopoietic stem cell transplantation. *Support Care Cancer* 22(1):15–21. <https://doi.org/10.1007/s00520-013-1940-2>
  20. Djuric M, Hillier-Kolarov V, Belic A, Jankovic L (2006) Mucositis prevention by improved dental care in acute leukemia patients. *Support Care Cancer* 14(2):137–146
  21. Zecha JAEM, Raber-Durlacher JE, Laheij AMGA, Westermann AM, Epstein JB, de Lange J, Smeele LE (2019) The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy. *Support Care Cancer* 27(10):3667–3679. <https://doi.org/10.1007/s00520-019-04925-8>
  22. Brandão TB, Morais-Faria K, Ribeiro ACP, Rivera C, Salvajoli JV, Lopes MA, Epstein JB, Arany PR, de Castro G Jr, Migliorati CA, Santos-Silva AR (2018) Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses. *Support Care Cancer* 26(7):2417–2423. <https://doi.org/10.1007/s00520-018-4046-z>
  23. Lalla RV, Saunders DP, Peterson DE (2014) Chemotherapy or radiation-induced oral mucositis. *Dent Clin N Am* 58(2):341–349. <https://doi.org/10.1016/j.cden.2013.12.005>
  24. Brandão TB, Vechiato Filho AJ, Batista VE, de Oliveira MC (2016) Santos-Silva AR (2016) Obturator prostheses versus free tissue transfers: a systematic review of the optimal approach to improving the quality of life for patients with maxillary defects. *J Prosthet Dent* 115(2):247–253
  25. Reyes-Gibby CC, Melkonian SC, Hanna EY, Yeung SJ, Lu C, Chambers MS, Banala SR, Gunn GB, Shete SS (2017) Cohort study of oncologic emergencies in patients with head and neck cancer. *Head Neck* 39(6):1195–1204
  26. Chen YK, Hou HA, Chow JM, Chen YC, Hsueh PR, Tien HF (2011) The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. *Eur J Clin Microbiol Infect Dis* 30(6):753–759

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.